Rigel Pharmaceuticals (RIGL) Change in Accured Expenses (2010 - 2026)
Rigel Pharmaceuticals' quarterly Change in Accured Expenses came in at -$5.9 million in Q1 2026, down 43.5% year-on-year from -$10.5 million in Q1 2025, and down 2698.58% quarter-over-quarter from -$211000.0 in Q4 2025.
Rigel Pharmaceuticals has reported Change in Accured Expenses for 17 years, with the latest figure at -$5.9 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Accured Expenses fell 43.5% year-over-year to -$5.9 million; the trailing twelve-month figure through Mar 2026 stood at -$2.1 million (down 366.71% YoY), and the FY2025 full-year result was -$285000.0, down 119.48% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$5.9 million, down from -$211000.0 in the prior quarter.
- The five-year high for Change in Accured Expenses was $2.3 million in Q2 2025, with the low at -$5.9 million in Q1 2026.
- Average Change in Accured Expenses over 5 years is -$556176.5, with a median of $429000.0 recorded in 2023.
- Peak annual rise in Change in Accured Expenses reached 3627.87% in 2022, while the deepest fall reached 480.8% in 2022.
- Tracing RIGL's Change in Accured Expenses over 5 years: stood at -$4.7 million in 2022, then soared by 118.23% to $853000.0 in 2023, then soared by 159.67% to $2.2 million in 2024, then slumped by 109.53% to -$211000.0 in 2025, then plunged by 2698.58% to -$5.9 million in 2026.
- The last three Change in Accured Expenses figures came in at -$5.9 million (Q1 2026), -$211000.0 (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Rigel Pharmaceuticals | 551.62 Mn | 404.94 Mn | 54.21 Mn | -5.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.91 Mn |
| Mar 31, 2026 | -5.91 Mn |
| Dec 31, 2025 | -211,000.00 |
| Dec 31, 2025 | -211,000.00 |
| Sep 30, 2025 | 1.73 Mn |
| Sep 30, 2025 | 1.73 Mn |
| Jun 30, 2025 | 2.31 Mn |
| Jun 30, 2025 | 2.31 Mn |
| Mar 31, 2025 | -4.12 Mn |
| Mar 31, 2025 | -4.12 Mn |
| Dec 31, 2024 | 2.22 Mn |
| Dec 31, 2024 | 2.22 Mn |
| Sep 30, 2024 | 1.55 Mn |
| Sep 30, 2024 | 1.55 Mn |
| Jun 30, 2024 | 1.13 Mn |
| Jun 30, 2024 | 1.13 Mn |
| Mar 31, 2024 | -3.43 Mn |
| Mar 31, 2024 | -3.43 Mn |
| Dec 31, 2023 | 853,000.00 |
| Dec 31, 2023 | 853,000.00 |
| Sep 30, 2023 | 429,000.00 |
| Sep 30, 2023 | 429,000.00 |
| Jun 30, 2023 | 1.73 Mn |
| Jun 30, 2023 | 1.73 Mn |
| Mar 31, 2023 | -3.21 Mn |
| Mar 31, 2023 | -3.21 Mn |
| Dec 31, 2022 | -4.68 Mn |
| Dec 31, 2022 | -4.68 Mn |
| Sep 30, 2022 | -1.74 Mn |
| Sep 30, 2022 | -1.74 Mn |
| Jun 30, 2022 | -396,000.00 |
| Jun 30, 2022 | -396,000.00 |
| Mar 31, 2022 | 2.27 Mn |
| Mar 31, 2022 | 2.27 Mn |
| Dec 31, 2021 | 1.23 Mn |
| Dec 31, 2021 | 1.23 Mn |
| Sep 30, 2021 | 1.70 Mn |
| Sep 30, 2021 | 1.70 Mn |
| Jun 30, 2021 | -1.89 Mn |
| Jun 30, 2021 | -1.89 Mn |
| Mar 31, 2021 | 61,000.00 |
| Mar 31, 2021 | 61,000.00 |
| Dec 31, 2020 | 1.96 Mn |
| Dec 31, 2020 | 1.96 Mn |
| Sep 30, 2020 | -1.46 Mn |
| Sep 30, 2020 | -1.46 Mn |
| Jun 30, 2020 | 4.13 Mn |
| Jun 30, 2020 | 4.13 Mn |
| Mar 31, 2020 | -3.31 Mn |
| Mar 31, 2020 | -3.31 Mn |
| Dec 31, 2019 | 6.01 Mn |
| Dec 31, 2019 | 6.01 Mn |
| Sep 30, 2019 | -4.22 Mn |
| Sep 30, 2019 | -4.22 Mn |
| Jun 30, 2019 | 6.85 Mn |
| Jun 30, 2019 | 6.85 Mn |
| Mar 31, 2019 | -5.52 Mn |
| Mar 31, 2019 | -5.52 Mn |
| Dec 31, 2018 | -156,000.00 |
| Dec 31, 2018 | -156,000.00 |
| Sep 30, 2018 | 2.04 Mn |
| Sep 30, 2018 | 2.04 Mn |
| Jun 30, 2018 | -3.80 Mn |
| Jun 30, 2018 | -3.80 Mn |
| Mar 31, 2018 | 2.18 Mn |
| Mar 31, 2018 | 2.18 Mn |
| Dec 31, 2017 | 2.32 Mn |
| Dec 31, 2017 | 2.32 Mn |
| Sep 30, 2017 | 695,000.00 |
| Sep 30, 2017 | 695,000.00 |
| Jun 30, 2017 | 1.43 Mn |
| Jun 30, 2017 | 1.43 Mn |
| Mar 31, 2017 | -1.46 Mn |
| Mar 31, 2017 | -1.46 Mn |
| Dec 31, 2016 | -2.07 Mn |
| Dec 31, 2016 | -2.07 Mn |
| Sep 30, 2016 | 3.04 Mn |
| Sep 30, 2016 | 3.04 Mn |
| Jun 30, 2016 | -33,000.00 |
| Jun 30, 2016 | -33,000.00 |
| Mar 31, 2016 | -3.10 Mn |
| Mar 31, 2016 | -3.10 Mn |
| Dec 31, 2015 | -930,000.00 |
| Dec 31, 2015 | -930,000.00 |
| Sep 30, 2015 | 1.53 Mn |
| Sep 30, 2015 | 1.53 Mn |
| Jun 30, 2015 | -881,000.00 |
| Jun 30, 2015 | -881,000.00 |
| Mar 31, 2015 | 882,000.00 |
| Mar 31, 2015 | 882,000.00 |
| Dec 31, 2014 | -151,000.00 |
| Dec 31, 2014 | -151,000.00 |
| Sep 30, 2014 | -189,000.00 |
| Sep 30, 2014 | -189,000.00 |
| Jun 30, 2014 | 697,000.00 |
| Jun 30, 2014 | 697,000.00 |
| Mar 31, 2014 | -374,000.00 |
| Mar 31, 2014 | -374,000.00 |
| Dec 31, 2013 | 3.71 Mn |
| Dec 31, 2013 | 3.71 Mn |
| Sep 30, 2013 | -3.65 Mn |
| Sep 30, 2013 | -3.65 Mn |
| Jun 30, 2013 | 3.25 Mn |
| Jun 30, 2013 | 3.25 Mn |
| Mar 31, 2013 | -3.50 Mn |
| Mar 31, 2013 | -3.50 Mn |
| Dec 31, 2012 | -55,000.00 |
| Dec 31, 2012 | -55,000.00 |
| Sep 30, 2012 | 421,000.00 |
| Sep 30, 2012 | 421,000.00 |
| Jun 30, 2012 | -988,000.00 |
| Jun 30, 2012 | -988,000.00 |
| Mar 31, 2012 | 1.06 Mn |
| Mar 31, 2012 | 1.06 Mn |
| Dec 31, 2011 | 4.32 Mn |
| Dec 31, 2011 | 4.32 Mn |
| Sep 30, 2011 | -402,000.00 |
| Sep 30, 2011 | -402,000.00 |
| Jun 30, 2011 | 819,000.00 |
| Jun 30, 2011 | 819,000.00 |
| Mar 31, 2011 | -2.28 Mn |
| Mar 31, 2011 | -2.28 Mn |
| Dec 31, 2010 | 2.66 Mn |
| Dec 31, 2010 | 2.66 Mn |
| Sep 30, 2010 | 1.15 Mn |
| Sep 30, 2010 | 1.15 Mn |